Avillion, which focuses on clinical co-development of therapeutics, has expanded its leadership team, appointing Ramani Varanasi, MSc, MBA, chief business officer.

Varanasi has 18 years of biotechnology and pharmaceutical industry experience  in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions, as well as in business development, management and strategic leadership.

Ramani has held research and senior level positions in business and corporate development  at Merck, Millennium/Takeda, Momenta Pharmaceuticals, Archemix and RXi Pharmaceuticals.

"We are excited to have Ramani on the Avillion team, where our key focus is the execution of co-development and financing deals with pharma and biotech companies,” said Lewis Cameron, CEO of Avillion. “Her experience and leadership in business and corporate development will support Avillion in its goal of establishing partnerships on late-stage clinical assets."